Morales-Miranda Adalid Y, Bueno-Arias Guadalupe M, Aguirre-Félix Óscar G, Tovar-Franco Rocío
Unidad de Especialidades Médicas. Universidad del Ejército y Fuerza Aérea, Secretaría de la Defensa Nacional, Ciudad de México, México.
Escuela Militar de Graduados de Sanidad. Universidad del Ejército y Fuerza Aérea, Secretaría de la Defensa Nacional, Ciudad de México, México.
Bol Med Hosp Infant Mex. 2019;76(4):182-187. doi: 10.24875/BMHIM.19000005.
Currently, no standardized treatment for severe alopecia areata (AA) exists. Numerous successful cases of the use of tofacitinib have been reported in the world literature, but not in Mexico. Four Mexican adolescents with severe AA treated with oral tofacitinib are reported in the present work.
Series of cases of adolescents with severe AA treated with oral tofacitinib. The severity of alopecia tool was used to determine the response to treatment.
Four patients from 13 to 19 years old, were included. In all cases, hair growth was observed, and the alopecia severity decreased after the treatment with tofacitinib. In two patients, an intermediate response (from 51 to 90%) was observed; in the other, a moderate response (from 6 to 50%) was observed, without serious adverse effects. The limitations of the study were the small sample size and the retrospective nature of data collection.
Tofacitinib showed to be a good treatment alternative for AA, total and universal, refractory to other therapies.
目前，对于重度斑秃（AA）尚无标准化治疗方法。世界文献中已报道了许多使用托法替布治疗成功的案例，但在墨西哥尚未见报道。本文报道了4例接受口服托法替布治疗的重度AA的墨西哥青少年患者。
对接受口服托法替布治疗的重度AA青少年患者进行系列病例研究。使用脱发严重程度工具来确定治疗反应。
纳入了4例年龄在13至19岁之间的患者。在所有病例中，均观察到毛发生长，且托法替布治疗后脱发严重程度降低。2例患者观察到中度反应（51%至90%）；另1例观察到轻度反应（6%至50%），且无严重不良反应。本研究的局限性在于样本量小以及数据收集的回顾性。
对于其他疗法难治的全秃和普秃型AA，托法替布显示出是一种良好的治疗选择。
Zotero 插件